Last updated: February 20, 2026
QULIPTA (atogepant) is a calcitonin gene-related peptide (CGRP) receptor antagonist developed by Eli Lilly for migraine prevention. Its supply chain encompasses manufacturing plants, active pharmaceutical ingredient (API) producers, and formulation facilities.
Manufacturing and API Suppliers
Cell Culture and API Production
Eli Lilly sources atogepant’s active pharmaceutical ingredients from multiple contract manufacturing organizations (CMOs), primarily located in North America and Europe. The key suppliers include:
- Thermo Fisher Scientific: Supplies reagents and raw materials for API synthesis.
- Excella GmbH: Provides synthesis of intermediates for atogepant.
- Other Contract Manufacturers: Specific ACMOs involved in API finalization remain undisclosed, typical of proprietary supply chains.
Formulation and Packaging
QULIPTA’s final formulation manufacturing occurs at Eli Lilly's controlled facilities, often in partnership with regional CDMOs to ensure supply continuity and compliance with regulatory standards.
Key Supplier Characteristics
| Supplier Name |
Role |
Location |
Capacity |
Regulatory Status |
| Eli Lilly and Company |
Drug development, Final formulation manufacturing |
U.S., Europe |
Multiple global facilities |
FDA, EMA approved facilities |
| Contract API Manufacturers |
API synthesis, intermediates production |
North America, Europe |
Varies by site |
cGMP compliant |
| Raw Material Suppliers |
Raw materials and reagents |
Global |
Variable |
ISO and cGMP certified |
Supply Chain Risks and Considerations
- Geographic concentration in North American and European manufacturing raises risks related to geopolitical issues or regional disruptions.
- Limited number of API manufacturers could lead to bottlenecks if supply chains are interrupted.
- Eli Lilly actively manages supplier qualification and dual sourcing to mitigate risks.
Regulatory and Supply Agreements
- The company maintains supply agreements with multiple CMOs to ensure redundancy.
- API suppliers are subject to rigorous regulatory inspections (FDA and EMA audits).
- Any change in suppliers or manufacturing sites requires filing supplementals with regulators.
Market Impact and Supply Dynamics
QULIPTA entered the market in 2022, with initial supply available through Lilly’s distribution channels. Ongoing capacity expansion and supply chain diversification are ongoing to meet rising demand.
Summary
The primary suppliers for QULIPTA include Eli Lilly's manufacturing facilities for formulation, and a limited number of CMOs in North America and Europe for API synthesis. The supply chain design emphasizes multiple sourcing, regulatory compliance, and capacity growth to support global distribution.
Key Takeaways
- Eli Lilly controls manufacturing of QULIPTA with partnerships to multiple API CMOs.
- API production is concentrated in North America and Europe, with associated supply risks.
- Regulatory compliance at all supplier sites minimizes risk of supply disruptions.
- The market’s growth will depend on capacity expansion and supply chain resilience.
- Supply agreements emphasize redundancy, securing distribution despite potential disruptions.
FAQs
1. Who manufactures the active ingredient (API) for QULIPTA?
Multiple contract manufacturers in North America and Europe produce the API under Eli Lilly’s oversight.
2. Are there multiple suppliers for the raw materials used in QULIPTA?
Yes, raw materials are sourced globally from certified suppliers, but specific vendor details are proprietary.
3. Does Eli Lilly own the manufacturing plants involved in QULIPTA’s production?
Eli Lilly operates several manufacturing facilities for formulation and final drug production; API synthesis is primarily performed by CMOs.
4. Has supply chain risk been addressed?
Yes. Supplier qualification, multi-sourcing, and capacity expansion are key strategies used to mitigate potential risks.
5. Are there plans to diversify the supply chain further?
Eli Lilly continues to evaluate additional suppliers and facilities to ensure supply security as demand grows.
References
- Eli Lilly and Company. (2022). QULIPTA (atogepant) prescribing information.
- U.S. Food and Drug Administration. (2022). Approved drug product lists.
- European Medicines Agency. (2022). Good Manufacturing Practice inspections.
- IQVIA. (2022). Global pharmaceutical supply chain report.
- PharmTech. (2022). API sourcing and manufacturing strategies.
